查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1957729

2026年全球放射性配体疗法市场报告

Radioligand Therapy Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，放射性配体疗法的市场规模迅速扩张。预计该市场规模将从2025年的66.3亿美元成长到2026年的73.2亿美元，复合年增长率（CAGR）为10.4%。成长要素包括放射性配体供应受限、对传统癌症疗法的依赖、人们对标靶治疗益处的认识不断提高、医院对核医学技术的应用日益广泛，以及早期放射性配体疗法药物获得监管部门核准。

预计未来几年放射性配体治疗市场将快速成长，到2030年将达到107.2亿美元，复合年增长率（CAGR）为10.0%。预测期内的成长要素包括新型α和β发射装置的研发进展、联合释放疗法的推广、与精准肿瘤学的融合、神经系统和心血管领域临床试验的增加，以及对居家医疗和门诊放射性配体治疗服务投资的增加。预测期内的关键趋势包括标靶放射性配体治疗在肿瘤学领域的应用日益广泛、基于α和β发射装置的治疗方法不断扩展、放射性配体治疗与个体化医疗方法的融合、医院和研究机构开展的放射性配体治疗项目的增长，以及减少副作用和改善患者预后的重要性日益凸显。

癌症发生率的急剧上升预计将推动放射性配体疗法市场的发展。癌症是一种不受控制的异常细胞增生侵袭并转移至周围组织的疾病。癌症发生率的上升与长期暴露于环境毒素密切相关，这些毒素会诱导DNA损伤、细胞功能障碍和异常增殖。放射性配体疗法透过受体结合配体诱导辐射，并精确照射肿瘤，抑制癌症，从内部杀死癌细胞，同时保护健康组织。例如，截至2025年10月，英国国家医疗服务体系（NHS）记录了2023年新增癌症病例354,820例（平均每天972例），比2022年增加了8,605例。因此，癌症发生率的上升正在推动放射性配体疗法市场的成长。

放射性配体治疗市场的主要企业正在开发专门的设施，以优化精准癌症疗法的生产和供应，提高效率、品质和安全性。放射性配体治疗设施是专门用于癌症治疗的放射性药物管理中心，配备了最先进的影像设备、屏蔽系统、专家团队和严格的安全措施。例如，2024年1月，瑞士製药巨头诺华公司在获得美国食品药物管理局（FDA）的商业核准后，对其位于印第安纳州的大规模放射性配体治疗（RLT）工厂进行了自动化改造。这座占地7万平方英尺的工厂是诺华公司规模最大、技术最先进的RLT生产基地，透过全自动化实现了快速、大规模的生产，并扩大了对美国和加拿大患者的供应。

目录

第一章：执行摘要

第二章 市场特征

  • 市场定义和范围
  • 市场区隔
  • 主要产品和服务概述
  • 全球放射性配体治疗市场：吸引力评分及分析
  • 成长潜力分析、竞争评估、策略适宜性评估、风险状况评估

第三章 市场供应链分析

  • 供应链与生态系概述
  • 清单：主要原料、资源和供应商
  • 主要经销商和通路合作伙伴名单
  • 主要最终用户列表

第四章：全球市场趋势与策略

  • 关键科技与未来趋势
    • 生物技术、基因组学和精准医疗
    • 数位化、云端运算、巨量资料、网路安全
    • 工业4.0和智慧製造
    • 人工智慧（AI）和自主人工智慧
    • 物联网、智慧基础设施、互联生态系统
  • 主要趋势
    • 标靶放射性配体疗法在肿瘤学的应用拓展
    • 基于α射线和β射线发射体的治疗方法的扩展
    • 放射性配体疗法与个人化医疗方法的整合
    • 医院和研究机构的放射性配体治疗项目增加
    • 人们越来越关注如何最大限度地减少副作用并改善患者预后。

第五章 终端用户产业市场分析

  • 医院
  • 诊断检查室
  • 研究机构
  • 居家医疗环境
  • 专科癌症中心

第六章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税的影响、关税战和贸易保护主义对供应链的影响，以及 COVID-19 疫情对市场的影响。

第七章：全球策略分析架构、目前市场规模、市场对比及成长率分析

  • 全球放射性配体治疗市场：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 全球放射性配体治疗市场规模、对比及成长率分析
  • 全球放射性配体疗法市场表现：规模与成长，2020-2025年
  • 全球放射性配体疗法市场预测：规模与成长，2025-2030年，2035年预测

第八章：全球市场总规模（TAM）

第九章 市场细分

  • 按放射性配体类型
  • α粒子发射装置、β粒子发射装置、俄歇粒子发射装置、复合发射装置
  • 按分子标靶分类
  • 荷尔蒙受体、生长因子受体、抗原肿瘤标记和其他分子标靶
  • 透过行政途径
  • 静脉注射（IV）、肌肉注射（IM）、皮下注射、口服
  • 透过使用
  • 肿瘤科、心血管疾病科、神经系统疾病科、感染疾病
  • 最终用户
  • 医院、诊断检查室、研究机构、居家医疗环境
  • 按类型细分：α粒子发射材料
  • 锕-225 (Ac-225)、镭-223 (Ra-223)、砹-211 (At-211)、铋-213 (Bi-213)
  • 依型别细分：β射线发射体
  • 镏-177 (Lu-177)、碘-131 (I-131)、钇-90 (Y-90)、钐-153 (Sm-153)
  • 按类型细分：螺旋式发射器
  • 碘-125 (I-125)、铟-111 (In-111)、镓-67 (Ga-67)、铊-201 (Tl-201)
  • 按类型细分：综合排放
  • 铽-161 (Tb-161)、铜-67 (Cu-67)、铼-186 (Re-186)、铅-212 (Pb-212)

第十章 区域与国别分析

  • 全球放射性配体治疗市场：按地区划分，实际结果和预测，2020-2025年、2025-2030年、2035年
  • 全球放射性配体治疗市场：按国家/地区划分，实际结果和预测，2020-2025 年、2025-2030 年、2035 年

第十一章 亚太市场

第十二章：中国市场

第十三章：印度市场

第十四章：日本市场

第十五章：澳洲市场

第十六章：印尼市场

第十七章：韩国市场

第十八章 台湾市场

第十九章 东南亚市场

第20章 西欧市场

第21章英国市场

第22章：德国市场

第23章：法国市场

第24章：义大利市场

第25章：西班牙市场

第26章：东欧市场

第27章：俄罗斯市场

第28章 北美市场

第29章：美国市场

第三十章：加拿大市场

第31章：南美市场

第32章：巴西市场

第33章 中东市场

第34章：非洲市场

第三十五章 市场监理与投资环境

第36章：竞争格局与公司概况

  • 放射性配体疗法市场：竞争格局与市场份额，2024 年
  • 放射性配体疗法市场：公司估值矩阵
  • 放射性配体疗法市场：公司概况
    • Novartis AG
    • Lantheus Holdings Inc.
    • Curium LLC
    • Eckert & Ziegler Strahlen-und Medizintechnik AG
    • Telix Pharmaceuticals

第37章 其他大型企业和创新企业

  • Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc.

第38章：全球市场竞争基准分析与仪錶板

第39章 重大併购

第四十章：高潜力市场国家、细分市场与策略

  • 2030年放射性配体治疗市场：提供新机会的国家
  • 2030年放射性配体治疗市场：充满新机会的细分市场
  • 2030年放射性配体疗法市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第41章附录

简介目录
Product Code: PH4MRTHE03_G26Q1

Radioligand therapy (RLT) is an advanced targeted cancer treatment that combines a radioactive isotope with a ligand engineered to bind specifically to cancer cell receptors. Once administered, it locates tumor cells and delivers radiation directly to them, minimizing harm to healthy tissues. This targeted strategy helps reduce side effects and improve outcomes, especially in cancers resistant to conventional therapies.

The main types of radioligands in radioligand therapy include alpha emitters, beta emitters, Auger emitters, and combined emissions. Alpha emitters release high-energy alpha particles over very short distances, typically just a few cell layers, making them highly effective for precise cell destruction. These radioligands target specific molecular markers such as hormone receptors, growth factor receptors, and tumor antigens, and can be administered via intravenous (IV), intramuscular (IM), subcutaneous, or oral routes. Radioligand therapy is applied in oncological, cardiovascular, neurological, and infectious disease treatments, and is utilized by hospitals, diagnostic laboratories, research institutions, and home care settings.

Tariffs have impacted the radioligand therapy market by increasing costs of imported radioactive isotopes, ligands, and specialized delivery equipment. Segments like alpha and beta emitter therapies are most affected, particularly in regions like North America and Europe, where imports dominate supply chains. This has led to higher treatment costs and potential delays in therapy availability. On the positive side, tariffs have encouraged local production, investment in domestic radiopharmaceutical facilities, and innovation in cost-efficient RLT solutions.

The radioligand therapy market research report is one of a series of new reports from The Business Research Company that provides radioligand therapy market statistics, including radioligand therapy industry global market size, regional shares, competitors with a radioligand therapy market share, detailed radioligand therapy market segments, market trends and opportunities, and any further data you may need to thrive in the radioligand therapy industry. This radioligand therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The radioligand therapy market size has grown rapidly in recent years. It will grow from $6.63 billion in 2025 to $7.32 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to limited availability of radioligands, reliance on conventional cancer therapies, growing awareness of targeted therapy benefits, increasing hospital adoption of nuclear medicine techniques, regulatory approvals for early rlt drugs.

The radioligand therapy market size is expected to see rapid growth in the next few years. It will grow to $10.72 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to development of novel alpha and beta emitters, expansion of combined emission therapies, integration with precision oncology, rising clinical trials for neurological and cardiovascular applications, increasing investment in home care and outpatient rlt services. Major trends in the forecast period include increasing adoption of targeted radioligand therapy for oncology, expansion of alpha and beta emitter-based therapies, integration of radioligand therapy with personalized medicine approaches, growth in hospital and research institution-based rlt programs, rising focus on minimizing side effects and enhancing patient outcomes.

The upsurge in cancer incidence is anticipated to boost the radioligand therapy market ahead. Cancer involves runaway abnormal cell proliferation that infiltrates nearby areas and metastasizes. Its rise links to prolonged environmental toxin exposure harming DNA, impairing cells, and spurring rogue growth. Radioligand therapy combats cancer by channeling radiation via receptor-binding ligands to zap tumors precisely, sparing healthy tissue for internal cell kill. For example, in October 2025, the National Health Service (NHS), a UK public health body, recorded 354,820 new cases in 2023-972 daily, up 8,605 from 2022. Thus, the climbing cancer incidence is fueling the radioligand therapy market.

Prominent companies in the radioligand therapy market are advancing setups like specialized radioligand therapy facilities to optimize output, quality, and safety in crafting and supplying pinpoint cancer drugs. Radioligand therapy facilities are dedicated hubs managing radioactive agents for focused cancer care, equipped with cutting-edge imaging, shielding, expert staff, and rigorous safeguards. For instance, in January 2024, Novartis AG, a Switzerland pharma leader, automated its massive Indiana radioligand therapy (RLT) plant post-FDA commercial nod. Spanning 70,000 square feet, it's Novartis's biggest, most sophisticated RLT site for swift, high-volume runs with full automation, ramping supply for US and Canada patients.

In December 2023, Eli Lilly and Company, a US pharma giant, snapped up POINT Biopharma Global Inc. for $1.4 billion. This bolsters Eli Lilly's oncology range with top-tier radioligand tech for sharper cancer precision meds. POINT Biopharma Global Inc. is a US firm honing radioligand cancer therapies.

Major companies operating in the radioligand therapy market are Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc.

North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the radioligand therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The radioligand therapy market consists of revenues earned by entities by providing services such as targeted treatment services, diagnostic imaging, and clinical and infrastructure services. The market value includes the value of related goods sold by the service provider or included within the service offering. The radioligand therapy market also includes sales of somatostatin receptor ligands, radiolabeled bombesin analogs, radiolabeled monoclonal antibodies, and prostate-specific membrane antigen (PSMA)-targeted ligands. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Radioligand Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses radioligand therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for radioligand therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The radioligand therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Type Of Radioligand: Alpha Emitters; Beta Emitters; Auger Emitters; Combined Emissions
  • 2) By Molecular Target: Hormone Receptors; Growth Factor Receptors; Antigen Tumor Markers; Other Molecular Targets
  • 3) By Route Of Administration: Intravenous (IV); Intramuscular (IM); Subcutaneous; Oral
  • 4) By Application: Oncology; Cardiovascular Disorders; Neurological Disorders; Infectious Diseases
  • 5) By End-User: Hospitals; Diagnostic Laboratories; Research Institutions; Home Care Settings
  • Subsegments:
  • 1) By Alpha Emitters: Actinium-225 (Ac-225); Radium-223 (Ra-223); Astatine-211 (At-211); Bismuth-213 (Bi-213)
  • 2) By Beta Emitters: Lutetium-177 (Lu-177); Iodine-131 (I-131); Yttrium-90 (Y-90); Samarium-153 (Sm-153)
  • 3) By Auger Emitters: Iodine-125 (I-125); Indium-111 (In-111); Gallium-67 (Ga-67); Thallium-201 (Tl-201)
  • 4) By Combined Emissions: Terbium-161 (Tb-161); Copper-67 (Cu-67); Rhenium-186 (Re-186); Lead-212 (Pb-212)
  • Companies Mentioned: Novartis AG; Lantheus Holdings Inc.; Curium LLC; Eckert & Ziegler Strahlen- und Medizintechnik AG; Telix Pharmaceuticals; Mariana Oncology Inc.; AdvanCell Pty Ltd.; Evergreen Theragnostics Inc.; Fusion Pharmaceuticals Inc.; RadioMedix Inc.; Ariceum Therapeutics GmbH; Radiopharm Theranostics Limited; Convergent Therapeutics Inc.; C-Ray Therapeutics Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Radioligand Therapy Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Radioligand Therapy Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Radioligand Therapy Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Radioligand Therapy Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.3 Industry 4.0 & Intelligent Manufacturing
    • 4.1.4 Artificial Intelligence & Autonomous Intelligence
    • 4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Increasing Adoption Of Targeted Radioligand Therapy For Oncology
    • 4.2.2 Expansion Of Alpha And Beta Emitter-Based Therapies
    • 4.2.3 Integration Of Radioligand Therapy With Personalized Medicine Approaches
    • 4.2.4 Growth In Hospital And Research Institution-Based RLT Programs
    • 4.2.5 Rising Focus On Minimizing Side Effects And Enhancing Patient Outcomes

5. Radioligand Therapy Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Diagnostic Laboratories
  • 5.3 Research Institutions
  • 5.4 Home Care Settings
  • 5.5 Specialty Cancer Centers

6. Radioligand Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Radioligand Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Radioligand Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Radioligand Therapy Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Radioligand Therapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Radioligand Therapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Radioligand Therapy Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Radioligand Therapy Market Segmentation

  • 9.1. Global Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions
  • 9.2. Global Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets
  • 9.3. Global Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral
  • 9.4. Global Radioligand Therapy Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases
  • 9.5. Global Radioligand Therapy Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings
  • 9.6. Global Radioligand Therapy Market, Sub-Segmentation Of Alpha Emitters, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)
  • 9.7. Global Radioligand Therapy Market, Sub-Segmentation Of Beta Emitters, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)
  • 9.8. Global Radioligand Therapy Market, Sub-Segmentation Of Auger Emitters, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)
  • 9.9. Global Radioligand Therapy Market, Sub-Segmentation Of Combined Emissions, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

10. Radioligand Therapy Market Regional And Country Analysis

  • 10.1. Global Radioligand Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Radioligand Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Radioligand Therapy Market

  • 11.1. Asia-Pacific Radioligand Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Radioligand Therapy Market

  • 12.1. China Radioligand Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Radioligand Therapy Market

  • 13.1. India Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Radioligand Therapy Market

  • 14.1. Japan Radioligand Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Radioligand Therapy Market

  • 15.1. Australia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Radioligand Therapy Market

  • 16.1. Indonesia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Radioligand Therapy Market

  • 17.1. South Korea Radioligand Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Radioligand Therapy Market

  • 18.1. Taiwan Radioligand Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Radioligand Therapy Market

  • 19.1. South East Asia Radioligand Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Radioligand Therapy Market

  • 20.1. Western Europe Radioligand Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Radioligand Therapy Market

  • 21.1. UK Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Radioligand Therapy Market

  • 22.1. Germany Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Radioligand Therapy Market

  • 23.1. France Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Radioligand Therapy Market

  • 24.1. Italy Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Radioligand Therapy Market

  • 25.1. Spain Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Radioligand Therapy Market

  • 26.1. Eastern Europe Radioligand Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Radioligand Therapy Market

  • 27.1. Russia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Radioligand Therapy Market

  • 28.1. North America Radioligand Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Radioligand Therapy Market

  • 29.1. USA Radioligand Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Radioligand Therapy Market

  • 30.1. Canada Radioligand Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Radioligand Therapy Market

  • 31.1. South America Radioligand Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Radioligand Therapy Market

  • 32.1. Brazil Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Radioligand Therapy Market

  • 33.1. Middle East Radioligand Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Radioligand Therapy Market

  • 34.1. Africa Radioligand Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Radioligand Therapy Market, Segmentation By Type Of Radioligand, Segmentation By Molecular Target, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Radioligand Therapy Market Regulatory and Investment Landscape

36. Radioligand Therapy Market Competitive Landscape And Company Profiles

  • 36.1. Radioligand Therapy Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Radioligand Therapy Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Radioligand Therapy Market Company Profiles
    • 36.3.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Lantheus Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Curium LLC Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Eckert & Ziegler Strahlen- und Medizintechnik AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Telix Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis

37. Radioligand Therapy Market Other Major And Innovative Companies

  • Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc.

38. Global Radioligand Therapy Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Radioligand Therapy Market

40. Radioligand Therapy Market High Potential Countries, Segments and Strategies

  • 40.1 Radioligand Therapy Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Radioligand Therapy Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Radioligand Therapy Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer